Multiple Sclerosis patients who switched to Teva’s Copaxone from interferon-beta treatment showed a significant reduction in spasticity. In addition, interim results for the first 52 of 110 participants of Teva’s study revealed much reduced muscle stiffness, pain and discomfort.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000744232